coronavirus
cov
subfamili
coronavirina
famili
coronavirida
order
nidoviral
group
highli
divers
envelop
positivesens
singlestrand
rna
virus
caus
respiratori
enter
hepat
neurolog
diseas
vari
sever
broad
rang
anim
speci
includ
cov
subdivid
four
genera
alphacoronaviru
betacoronaviru
gammacoronaviru
past
year
two
novel
sever
acut
respiratori
syndrom
cov
sarscov
middl
east
respiratori
syndrom
cov
merscov
emerg
virus
caus
sever
human
lack
effect
drug
treatment
associ
high
morbid
mortal
rate
two
cov
well
potenti
caus
epidem
highlight
need
novel
drug
discoveri
treatment
cov
infect
sar
sarscov
emerg
first
southern
china
rapidli
spread
around
globe
ref
novemb
unusu
epidem
atyp
pneumonia
high
rate
nosocomi
transmiss
healthcar
worker
occur
foshan
guangdong
march
novel
cov
confirm
caus
agent
sar
thu
name
nephrologist
travel
southern
china
hong
kong
februari
becam
index
case
subsequ
larg
commun
healthcareassoci
outbreak
sar
hong
kong
high
infect
sar
highlight
superspread
event
major
teach
hospit
hong
kong
peopl
includ
mani
previous
healthi
healthcar
worker
infect
within
week
exposur
index
patient
manag
gener
medic
ward
communityacquir
intern
air
travel
sarscov
spread
countri
region
total
case
fatal
case
end
epidem
juli
ref
see
supplementari
inform
figur
part
b
retrospect
serolog
survey
suggest
crossspeci
transmiss
sarscov
variant
anim
speci
human
might
occur
frequent
wet
market
high
seropreval
detect
among
asymptomat
anim
close
variant
sarscov
isol
palm
civet
dongmen
market
shenzhen
china
ref
smallscal
sar
outbreak
late
earli
three
four
patient
direct
indirect
contact
palm
howev
viral
genet
sequenc
analysi
demonstr
sarscovlik
viru
circul
among
mask
palm
civet
market
long
time
serolog
studi
show
cage
market
civet
wild
civet
infect
sarscovlik
cov
highli
similar
sarscov
isol
chines
horsesho
bat
sinc
ref
sarslik
cov
bat
share
sequenc
homolog
human
civet
cov
isol
suggest
bat
probabl
natur
reservoir
close
ancestor
mer
isol
novel
patient
jeddah
saudi
arabia
die
sever
pneumonia
multiorgan
failur
june
first
report
septemb
ref
initi
name
human
coronaviru
erasmu
medic
center
viru
later
renam
merscov
intern
consensu
diseas
call
middl
east
respiratori
syndrom
mer
retrospect
analysi
cluster
nosocomi
case
april
jordan
confirm
merscov
also
respons
past
year
merscov
continu
spread
within
beyond
middl
east
ongo
report
sporad
case
commun
healthcareassoci
cluster
infect
individu
middl
east
especi
saudi
arabia
unit
arab
travelrel
case
cluster
also
increasingli
report
octob
laboratoryconfirm
case
mer
includ
death
report
world
health
see
supplementari
inform
figur
part
c
merscov
consid
primarili
zoonot
viru
capabl
nonsustain
persontoperson
serolog
virolog
studi
shown
camel
bat
like
anim
reservoir
although
primari
case
mer
individu
direct
contact
camel
exposur
consid
import
factor
spread
merscov
evidenc
substanti
increas
seropreval
antimerscov
antibodi
among
individu
occup
exposur
camel
camel
shepherd
slaughterhous
worker
rel
gener
popul
saudi
persontoperson
transmiss
merscov
occur
healthcar
facil
famili
recent
larg
healthcareassoci
outbreak
jeddah
south
korea
attribut
poor
complianc
infect
control
studi
need
fulli
understand
exact
mode
transmiss
potenti
sourc
merscov
optim
treatment
prevent
strategi
clinic
featur
sar
mer
patient
sar
mer
present
variou
clinic
featur
rang
asymptomat
mild
respiratori
ill
fulmin
sever
acut
respiratori
diseas
extrapulmonari
diseas
predominantli
respiratori
manifest
extrapulmonari
featur
may
occur
sever
see
supplementari
inform
tabl
notabl
earli
treatment
especi
import
patient
sever
mer
diseas
progress
respiratori
distress
renal
failur
death
much
rapidli
sar
three
fourfold
higher
casefat
rate
mer
rel
sar
may
relat
higher
median
age
preval
comorbid
patient
mer
well
differ
pathogenesi
two
comorbid
associ
sever
mer
includ
obes
diabet
mellitu
system
immunocompromis
condit
chronic
cardiac
pulmonari
although
rate
secondari
transmiss
among
household
contact
index
mer
patient
approxim
estim
pandem
potenti
merscov
lower
sarscov
rapidli
progress
clinic
cours
high
fatal
mer
continu
pose
major
threat
atrisk
see
supplementari
inform
tabl
current
manag
strategi
sar
mer
support
care
includ
organ
support
prevent
complic
especi
acut
respiratori
distress
syndrom
organ
failur
secondari
nosocomi
infect
remain
import
manag
strategi
sar
mer
current
specif
antivir
treatment
proven
effect
random
control
numer
compound
found
inhibit
entri
andor
replic
sarscov
merscov
cell
cultur
anim
model
activ
vitro
even
anim
experi
necessarili
translat
efficaci
owe
high
morbid
mortal
rate
sar
mer
antivir
drug
immunomodul
use
empir
evalu
uncontrol
tabl
substanti
effort
underway
discov
new
therapeut
agent
cov
infect
investig
base
understand
basic
virolog
cov
importantli
treatment
investig
therapi
requir
applic
standard
research
treatment
protocol
systemat
clinic
virolog
data
collect
control
research
trial
approv
local
ethic
committe
key
cov
target
new
drug
develop
despit
high
speci
divers
cov
share
key
genom
element
essenti
design
therapeut
target
fig
larg
replicas
polyprotein
encod
open
read
frame
cleav
two
viral
proteas
papainlik
proteas
plpro
proteas
produc
nonstructur
protein
nsp
rnadepend
rna
polymeras
rdrp
helicas
involv
transcript
replic
fig
numer
enzym
inhibitor
target
protein
shown
anticov
activ
vitro
surfac
structur
spike
glycoprotein
particular
interest
antivir
develop
critic
role
receptor
interact
compos
aminotermin
receptorbind
carboxytermin
membran
fusion
subunit
cleavag
proteas
site
junction
requir
activ
membran
fusion
viru
entri
syncytium
bind
subunit
receptorbind
domain
rbd
host
receptor
trigger
conform
chang
subunit
stalk
region
bring
viral
cell
membran
close
proxim
enabl
monoclon
antibodi
mab
subunit
rbd
fusion
inhibitor
target
subunit
potent
anticov
activ
vitro
andor
key
function
host
receptor
util
human
pathogen
cov
includ
angiotensinconvert
enzym
use
sarscov
human
cov
hcov
dipeptidyl
peptidas
use
merscov
aminopeptidas
n
use
oacetyl
sialic
acid
use
host
receptor
import
determin
pathogen
tissu
tropism
host
rang
viru
mab
agent
target
host
receptor
potenti
anticov
agent
long
induc
immunopatholog
effect
anim
model
cov
enter
host
cell
use
endosom
pathway
andor
cell
surfac
nonendosom
fig
low
ph
phdepend
endosom
cystein
proteas
cathepsin
help
overcom
energet
unfavour
membran
fusion
reaction
facilit
endosom
cell
entri
host
proteas
transmembran
proteas
serin
also
known
airway
trypsinlik
proteas
cleav
subunit
activ
cell
surfac
nonendosom
viru
entri
plasma
inhibitor
proteas
abrog
proteolyt
cleavag
partial
block
cell
merscov
also
activ
furin
serin
endoproteas
implic
process
fusion
protein
cell
entri
rna
virus
includ
hiv
avian
influenza
viru
ebola
viru
marburg
viru
furin
also
involv
merscov
cleavag
egress
infect
monotherapi
andor
combinatori
treatment
inhibitor
host
proteas
involv
variou
cell
entri
pathway
potent
anticov
activ
vitro
evalu
anim
cov
disassembl
insid
host
cell
releas
nucleocapsid
viral
rna
cytoplasm
translat
genom
rna
numer
nsp
produc
cleavag
form
complex
attach
hydrophob
domain
cov
complex
limit
membran
deriv
endoplasm
reticulum
produc
typic
cov
replic
structur
includ
doublemembran
vesicl
dmv
convolut
novel
agent
target
membranebound
cov
rna
synthesi
inhibit
dmv
format
broad
rang
human
anim
fulllength
posit
strand
genom
rna
transcrib
form
fulllength
negativestrand
templat
synthesi
new
genom
rna
overlap
subgenom
negativestrand
subgenom
mrna
synthes
translat
produc
structur
accessori
helic
nucleocapsid
form
assembl
nucleocapsid
protein
n
genom
rna
interact
envelop
protein
e
membran
protein
form
assembl
virion
releas
extracellular
compart
exocytosi
viral
replic
cycl
small
interf
rna
sirna
target
structur
gene
could
use
treatment
cov
infect
optim
vivo
deliveri
sirna
may
enabl
clinic
use
approach
anticov
drug
screen
two
humanpathogen
cov
known
sar
epidem
usual
caus
selflimit
upper
respiratori
tract
therefor
research
research
facil
especi
involv
antivir
develop
underprepar
sarscov
suddenli
emerg
subsequ
three
gener
approach
use
discov
potenti
anticov
treatment
option
humanpathogen
cov
especi
sarscov
emerg
merscov
associ
sever
diseas
hcov
first
approach
drug
discoveri
test
exist
broadspectrum
antivir
drug
use
treat
viral
infect
use
standard
assay
measur
effect
drug
cytopath
viru
yield
plaqu
format
live
andor
pseudotyp
cov
exampl
drug
identifi
use
approach
includ
interferon
alfa
interferon
beta
interferon
gamma
ribavirin
inhibitor
drug
obviou
advantag
readili
avail
known
pharmacokinet
pharmacodynam
properti
side
effect
dose
regimen
howev
specif
anticov
effect
may
associ
sever
advers
effect
second
anticov
drug
discoveri
approach
involv
screen
chemic
librari
compris
larg
number
exist
compound
databas
contain
inform
transcript
signatur
differ
cell
approach
provid
rapid
highthroughput
screen
mani
readili
avail
compound
evalu
antivir
assay
variou
class
drug
identifi
drug
repurpos
programm
includ
mani
import
physiolog
andor
immunolog
effect
affect
neurotransmitt
regul
oestrogen
receptor
kinas
signal
lipid
sterol
metabol
protein
process
dna
synthesi
major
disadvantag
approach
although
mani
identifi
drug
exhibit
anticov
activ
vitro
clinic
use
either
associ
immunosuppress
effect
anticov
halfmaxim
effect
concentr
valu
markedli
exceed
peak
serum
concentr
cmax
level
achiev
therapeut
dosag
notabl
except
found
effect
nonhuman
primat
model
nonrandom
clinic
trial
antihiv
proteas
inhibitor
tabl
third
approach
anticov
drug
discoveri
involv
de
novo
develop
novel
specif
agent
base
genom
biophys
understand
individu
cov
exampl
includ
sirna
molecul
inhibitor
target
specif
viral
enzym
involv
viral
replic
cycl
mab
target
host
receptor
inhibitor
host
cellular
proteas
inhibitor
viru
endocytosi
host
cell
human
human
mab
target
subunit
rbd
antivir
peptid
target
subunit
fig
although
drug
potent
vitro
andor
vivo
anticov
activ
pharmacokinet
pharmacodynam
properti
sideeffect
profil
yet
evalu
anim
human
trial
furthermor
develop
candid
drug
clinic
use
therapeut
option
reliabl
deliveri
mode
patient
usual
take
year
overal
three
drug
discoveri
approach
often
use
togeth
emerg
cov
outbreak
identifi
candid
drug
compound
broadli
classifi
virusbas
hostbas
treatment
option
viral
nucleosid
nucleotid
nucleic
acid
nucleosid
nucleotid
build
block
viral
nucleic
acid
fig
drug
target
nucleosid
nucleotid
andor
viral
nucleic
acid
gener
broadspectrum
activ
wide
rang
cov
virus
tabl
mycophenol
mofetil
antireject
drug
inhibit
inosin
monophosph
dehydrogenas
synthesi
guanin
activ
compound
mycophenol
acid
exhibit
antivir
activ
vitro
variou
virus
includ
hepat
b
viru
hbv
hepat
c
viru
hcv
mycophenol
acid
identifi
potenti
antimerscov
drug
use
highthroughput
screen
potent
antimerscov
activ
howev
subsequ
studi
nonhuman
primat
model
show
merscovinfect
common
marmoset
treat
mycophenol
mofetil
wors
outcom
sever
diseas
higher
viral
load
necropsi
lung
extrapulmonari
tissu
untreat
anim
renal
transplant
recipi
mainten
mycophenol
mofetil
therapi
also
develop
sever
fatal
thu
usual
dosag
mycophenol
mofetil
monotherapi
unlik
use
prophylaxi
treatment
cov
infect
ribozym
also
known
catalyt
rna
rna
enzym
rna
molecul
catalys
specif
biochem
reaction
chimer
hammerhead
ribozym
specif
recogn
base
sequenc
guc
present
loop
region
sarscov
mrna
substanti
reduc
express
recombin
sarscov
rna
howev
ribozym
rapidli
degrad
vivo
deliveri
method
would
optim
human
ribozym
could
becom
clinic
use
agent
target
specif
host
cell
membranebound
cov
replic
complex
also
investig
one
compound
inhibit
membranebound
cov
rna
synthesi
activ
broad
rang
cov
cell
cultur
exert
potent
anticov
activ
earli
step
viral
replic
cycl
impair
format
escap
mutant
resist
substitut
potenti
membranespan
domain
membranespan
integr
compon
cov
replic
complex
involv
dmv
format
includ
ref
emerg
resist
monitor
subsequ
vivo
studi
recent
new
class
broadspectrum
antivir
target
long
viral
doublestrand
rna
dsrna
report
exampl
dsrnaactiv
caspas
oligomer
draco
chimer
protein
viral
dsrnabind
domain
proapoptot
domain
select
induc
apoptosi
cell
contain
viral
dsrna
spare
uninfect
host
draco
activ
mani
rna
virus
vitro
andor
effect
mode
draco
deliveri
achiev
broadspectrum
anticov
drug
target
highli
conserv
cov
rna
sequenc
might
becom
realiti
viral
enzym
major
enzym
protein
cov
involv
viral
replic
potenti
druggabl
target
tabl
sarscov
merscov
plpro
enzym
exhibit
proteolyt
deubiquityl
deisgyl
crystallographi
facilit
character
plpro
enzym
identif
plpro
numer
sarscov
plpro
inhibitor
belong
differ
class
identifi
includ
smallmolecul
inhibitor
thiopurin
compound
natur
product
zinc
ion
zinc
conjug
inhibitor
naphthalen
howev
drug
inhibit
enzymat
activ
plpro
without
inhibit
viral
replic
vice
none
valid
anim
human
furthermor
plpro
inhibitor
narrowspectrum
activ
structur
differ
among
plpro
enzym
differ
exampl
sarscov
plpro
inhibitor
inact
merscov
structur
differ
flexibl
block
loop
domain
plpro
enzym
sarscov
major
cov
proteas
cleav
larg
replicas
polyprotein
viral
replic
sarscov
target
numer
class
proteas
inhibitor
includ
zinc
mercuri
conjug
diol
ester
anilid
benzotriazol
biphenyl
sulfon
glutam
acid
glutamin
peptid
trifluoromethylketon
group
pyrimidinon
pyrazol
inhibitor
demonstr
broadspectrum
vitro
activ
cov
highli
similar
key
residu
substrat
recognit
among
inhibitor
readili
avail
one
lopinavir
proteas
inhibitor
use
treat
hiv
infect
usual
market
ritonavirboost
form
lopinavir
andor
anticov
activ
vitro
well
merscovinfect
nonhuman
primat
nonrandom
trial
sar
postul
activ
contribut
least
partial
anticov
remain
seen
resist
emerg
patient
hiv
infect
routin
use
treat
cov
infect
rdrp
essenti
part
cov
complex
involv
product
genom
subgenom
rna
ribavirin
guanosin
analogu
broadspectrum
antivir
activ
use
treatment
sever
respiratori
syncyti
viru
infect
hcv
infect
viral
haemorrhag
fever
exact
mechan
action
undetermin
inhibit
mrna
cap
induct
mutat
rnadepend
viral
replic
consid
import
rna
virus
includ
highdos
ribavirin
use
treat
sar
patient
benefit
exhibit
moder
antimerscov
activ
high
dose
vitro
merscovinfect
rhesu
macaqu
obviou
surviv
benefit
small
cohort
mer
moreov
sever
side
effect
associ
use
highdos
ribavirin
limit
clinic
applic
patient
sever
cov
recent
novel
adenosin
analogu
immucillina
act
nonoblig
rna
chain
termin
inhibit
viral
rna
polymeras
wide
rang
rna
virus
includ
cov
sarscov
merscov
well
filovirus
ebola
marburg
develop
human
use
fasttrack
increas
number
treatment
option
recent
ebola
viru
epidem
west
africa
exist
nucleosid
analogu
acyclovir
could
modifi
incorpor
flexim
increas
bind
affin
overcom
resist
caus
point
mutat
biolog
import
bind
acycl
flexim
nucleosid
analogu
inhibit
merscov
vitro
micromolar
notabl
resist
nucleosid
analogu
due
mutat
rdrp
report
rna
virus
monitor
agent
use
treat
cov
infect
addit
nucleosid
analogu
sirna
molecul
target
sarscov
rdrp
use
inhibit
sarscov
helicas
catalys
unwind
duplex
oligonucleotid
singl
strand
atpdepend
reaction
cov
replic
cycl
helicas
inhibitor
attract
anticov
treatment
option
helicas
differ
cov
highli
homolog
base
mechan
action
cov
helicas
inhibitor
broadli
categor
two
group
first
group
includ
bananin
deriv
inhibit
unwind
atpas
activ
sarscov
helicas
result
inhibit
viral
replic
howev
toxic
result
inhibit
cellular
atpas
kinas
compound
limit
develop
human
use
second
group
cov
helicas
inhibitor
includ
compound
select
inhibit
unwind
activ
atpas
activ
cov
helicas
exampl
triazol
inhibit
broad
rang
cov
includ
sarscov
merscov
mous
hepat
toxic
evalu
anim
model
viral
spike
glycoprotein
membraneanchor
glycoprotein
major
immunogen
antigen
essenti
interact
viru
host
cell
receptor
fig
adopt
transfer
sera
contain
antimerscov
antibodi
block
viru
attach
acceler
viral
clearanc
lung
merscov
infect
balbc
mice
recent
transduc
adenovir
vector
express
human
ref
tabl
small
cohort
sar
patient
receiv
convalescentphas
plasma
contain
neutral
antibodi
probabl
target
cov
significantli
higher
discharg
rate
week
symptom
onset
lower
mortal
howev
use
convalescentphas
plasma
therapi
emerg
cov
outbreak
limit
good
convalesc
patient
high
serum
neutral
antibodi
titr
diseas
worsen
associ
immun
enhanc
result
treatment
product
contain
low
antibodi
titr
report
cell
line
anim
overcom
problem
mab
target
differ
region
sarscov
gener
immun
human
immunoglobulin
transgen
mice
clone
small
chain
variabl
region
naiv
convalesc
patient
well
immort
convalesc
sspecif
b
mab
target
specif
epitop
subunit
rbd
inhibit
receptor
bind
wherea
other
bind
subunit
interrupt
regardless
bind
site
mechan
mab
exhibit
neutral
activ
reduc
viral
titr
vitro
andor
small
anim
model
similarli
sever
mab
target
differ
epitop
subunit
rbd
merscov
monoclon
antibodi
bind
rbd
higher
affin
human
result
broader
higher
neutral
activ
vitro
importantli
combin
therapi
two
synergist
act
human
human
mab
target
noncrossresist
epitop
differ
region
may
help
reduc
frequenc
virus
mutat
escap
antibodymedi
treatment
mab
show
protect
effect
merscovinfect
human
mice
mice
transduc
adenovir
vector
express
human
ref
safeti
profil
treatment
effect
patient
evalu
antivir
peptid
target
differ
region
anoth
promis
therapeut
strategi
subunit
stalk
region
sarscov
merscov
class
viral
fusion
protein
contain
ntermin
fusion
peptid
heptad
repeat
domain
transmembran
domain
cytoplasm
antivir
peptid
analog
n
terminu
pretransmembran
domain
loop
region
separ
domain
sarscov
inhibit
viru
plaqu
format
micromolar
similarli
antivir
peptid
span
domain
merscov
inhibit
smediat
fusion
viral
entri
cell
peptid
call
deriv
domain
administ
intranas
viral
challeng
protect
mice
mice
defici
v
j
recombinationactiv
protein
recent
transduc
adenovir
vector
express
human
merscov
infect
reduct
viral
titr
lung
protect
enhanc
combin
peptid
interferon
combin
antivir
peptid
target
differ
region
subunit
may
synergist
vitro
overcom
theoret
risk
drug
importantli
analog
fusion
inhibitor
enfuvirtid
bind
glycoprotein
hiv
block
membran
fusion
hiv
cell
entri
success
market
treatment
primari
resist
enfuvirtid
rare
overcom
modifi
drug
contain
secondari
compensatori
exampl
success
drug
develop
includ
measur
counteract
drug
resist
therefor
favour
antivir
peptid
anticov
sirna
evalu
vivo
sirna
remain
preclin
develop
despit
report
antivir
activ
vitro
sarscovinfect
rhesu
macaqu
owe
lack
reliabl
drug
deliveri
method
anoth
class
anticov
agent
target
inhibit
cov
entri
carbohydratebind
agent
griffithsin
antivir
protein
origin
isol
red
alga
griffithsia
bind
specif
oligosaccharid
viral
surfac
glycoprotein
hiv
glycoprotein
inhibit
broad
rang
cov
includ
sarscov
vitro
sarscovinfect
optim
deliveri
mode
safeti
profil
agent
human
evalu
viral
envelop
membran
nucleocapsid
accessori
protein
e
n
accessori
protein
essenti
virion
assembl
may
also
addit
function
suppress
host
immun
respons
facilit
viral
replic
exampl
accessori
protein
possibl
also
accessori
protein
merscov
exhibit
interferon
antagonist
activ
sarscov
n
act
viral
suppressor
rna
silenc
suppress
rna
interfer
trigger
either
short
hairpin
rna
tabl
sirna
target
e
n
sarscov
inhibit
viral
replic
howev
similar
anticov
sirna
none
sirna
readi
human
use
better
deliveri
method
becom
avail
altern
increas
number
agent
target
specif
bind
site
function
protein
gener
crystallographi
function
assay
exampl
includ
viroporin
inhibitor
hexamethylen
amilorid
reduc
ion
channel
activ
e
sarscov
bind
distinct
ribonucleotidebind
pocket
ntermin
domain
n
ref
howev
agent
like
narrowspectrum
bind
site
function
protein
uniqu
individu
cov
novel
lipophil
thiazolidin
deriv
membranebind
photosensit
produc
singlet
oxygen
molecul
induc
chang
properti
lipid
membran
prevent
fusion
viral
target
cell
membran
exhibit
broadspectrum
activ
numer
envelop
virus
may
activ
broadspectrum
host
innat
immun
respons
host
innat
interferon
respons
crucial
control
viral
replic
although
cov
abl
suppress
interferon
respons
immun
evas
remain
suscept
interferon
treatment
interferon
respons
augment
administr
recombin
interferon
interferon
induc
tabl
recombin
interferon
alfa
interferon
beta
inhibit
replic
sarscov
merscov
vitro
anim
variou
combin
interferon
alfa
interferon
beta
antivir
ribavirin
andor
use
treat
patient
sar
mer
overal
combin
treatment
consist
interferon
ribavirin
consist
improv
appar
discrep
vitro
find
vivo
outcom
may
relat
high
ratio
drug
delay
symptom
onset
drug
delay
especi
relev
mer
patient
much
shorter
median
time
interv
symptom
onset
death
sar
use
recombin
interferon
lowest
ratio
merscov
among
test
prepar
recombin
interferon
evalu
combin
effect
antivir
clinic
trial
earli
stage
polyinosin
polycytidyl
acid
poli
c
synthet
analogu
dsrna
strongli
induc
type
interferon
substanti
reduc
merscov
load
balbc
mice
transduc
adenovir
vector
express
human
shortli
poli
c
administr
although
effect
standard
cell
cultur
protect
assay
intramuscular
inject
poli
c
stabil
polyllysin
carboxymethylcellulos
seem
well
toler
patient
malign
glioma
phase
ii
clinic
nitazoxanid
anoth
potent
type
interferon
induc
use
human
parasit
synthet
deriv
exhibit
broadspectrum
antivir
activ
rna
dna
virus
includ
canin
cov
influenza
virus
hbv
hcv
hiv
rotaviru
noroviru
evalu
phase
ii
phase
iii
clinic
trial
treatment
hcv
infect
influenza
good
safeti
innat
immunomodul
antisarscov
effect
anim
model
includ
antimicrobi
peptid
rhesu
protein
cage
nanoparticl
elicit
host
immun
respons
induc
bronchusassoci
lymphoid
combin
use
interferon
induc
innat
immunomodul
effect
antivir
agent
may
synergist
evalu
anim
model
host
signal
pathway
involv
viral
replic
addit
direct
potenti
interferon
respons
cell
signal
pathway
identifi
potenti
anticov
treatment
target
tabl
cyclophilin
interact
sarscov
modul
calcineurin
pathway
import
cellmedi
adapt
immun
calcineurin
inhibitor
cyclosporin
inhibit
broad
rang
cov
howev
clinic
applic
limit
immunosuppress
effect
high
ratio
standard
therapeut
dosag
antivir
activ
newer
nonimmunosuppress
calcineurin
inhibitor
activ
evalu
sarscov
similarli
agent
modul
cellular
signal
pathway
kinas
signal
pathway
inhibitor
also
exhibit
anticov
activ
commerci
howev
toxic
may
limit
use
patient
sever
cov
infect
host
factor
util
cov
viral
replic
cov
util
specif
host
factor
viru
entri
replic
fig
host
receptor
target
specif
monoclon
polyclon
antibodi
peptid
function
inhibitor
tabl
exampl
mab
inhibit
merscov
cell
entri
recombin
human
mab
seem
well
toler
patient
advanc
solid
treatment
sarscov
smallmolecul
entri
inhibitor
n
naae
inhibit
catalyt
activ
sarscov
smediat
fusion
synthet
peptid
analog
critic
segment
also
antisarscov
activ
micromolar
concentr
howev
none
receptordirect
compound
yet
test
patient
cov
infect
anticov
activ
like
narrowspectrum
differ
cov
util
differ
host
cell
receptor
furthermor
risk
immunopatholog
must
assess
especi
given
multipl
essenti
biolog
immunolog
function
receptor
entri
cov
host
cell
via
endosom
andor
cell
surfac
pathway
facilit
host
proteas
cleav
activ
cathepsin
cystein
proteas
involv
endosom
pathway
inhibit
cathepsin
inhibitor
relat
vinylsulfon
compound
seem
safe
effect
variou
parasit
infect
anim
model
broadspectrum
activ
envelop
rna
virus
cov
sarscov
merscov
filovirus
ebola
marburg
virus
serin
proteas
mediat
cell
surfac
entri
pathway
camostat
mesyl
synthet
lowmolecularweight
serin
proteas
inhibitor
use
treat
chronic
pancreat
human
minim
side
molecul
inhibit
sarscov
merscov
vitro
improv
surviv
sarscovinfect
furin
anoth
ubiquit
express
host
proteas
also
import
merscov
smediat
entri
block
furin
decanoylargvallysargchloromethylketon
inhibit
merscov
entri
fusion
anoth
group
candid
anticov
drug
target
endocytosi
cov
cell
entri
chlorpromazin
antipsychot
drug
use
treatment
schizophrenia
also
affect
assembl
clathrinco
pit
plasma
membran
activ
hcv
alphavirus
numer
cov
includ
sarscov
merscov
cardioton
steroid
bind
sodiumpotassiumtransport
atpas
subunit
ouabain
bufalin
also
inhibit
clathrinmedi
endocytosi
merscov
nanomolar
howev
use
clathrinmedi
endocytosi
inhibitor
patient
cov
infect
limit
either
high
ratio
toxic
altern
endocytosi
also
suppress
high
ph
chloroquin
antimalari
drug
sequest
proton
lysosom
increas
intracellular
ph
broadspectrum
antivir
activ
numer
cov
sarscov
merscov
rna
virus
howev
substanti
reduc
viral
replic
sarscovinfect
mice
possibl
cell
surfac
pathway
simultan
anticov
effect
pharmacokinet
pharmacodynam
profil
toxic
combin
differ
proteas
endocytosi
inhibitor
target
differ
cell
entri
pathway
evalu
vivo
anim
model
test
anticov
drug
suitabl
anim
model
especi
import
test
anticov
drug
drug
use
human
contrast
limit
number
anim
model
establish
mild
infect
caus
variou
small
anim
nonhuman
primat
model
evalu
studi
pathogenesi
treatment
sar
identif
function
receptor
sarscov
merscov
respect
essenti
develop
anim
model
repres
sever
human
number
differ
nonhuman
primat
found
permiss
sarscov
none
consist
reproduc
characterist
sever
human
diseas
mortal
model
predominantli
use
fulfil
koch
small
anim
includ
young
age
balbc
mice
knockout
mice
defici
b
andor
nk
cell
golden
syrian
hamster
ferret
could
product
infect
sarscov
develop
clinic
appar
best
avail
small
anim
model
sar
util
transgen
mice
express
human
andor
mouseadapt
sarscov
strain
capabl
caus
lethal
diseas
limit
avail
mice
mouseadapt
viru
strain
remain
major
obstacl
test
antisarscov
drug
similar
sar
nonhuman
primat
model
also
use
fulfil
koch
postul
investig
pathogenesi
mer
rhesu
macaqu
develop
mild
selflimit
diseas
optim
evalu
treatment
contrast
merscovinfect
common
marmoset
develop
dissemin
fatal
infect
close
resembl
sever
human
howev
avail
common
marmoset
limit
experi
small
primat
technic
demand
therefor
small
anim
model
mer
evalu
unlik
sarscov
small
anim
includ
balbc
mice
golden
syrian
hamster
ferret
rabbit
suscept
merscov
intranas
inocul
adenovir
vector
express
human
follow
merscov
inocul
novel
method
rapidli
render
mice
suscept
merscov
infect
diseas
rel
mild
confin
respiratori
transgen
mice
express
human
develop
sever
pulmonari
dissemin
infect
current
best
avail
small
anim
model
potenti
antimerscov
treatment
option
identifi
vitro
antivir
assay
evalu
transgen
mice
gener
challeng
clinic
develop
novel
anticov
drug
number
virolog
patientassoci
factor
pose
major
challeng
clinic
develop
novel
anticov
drug
first
cov
one
divers
rapidli
mutat
group
virus
novel
cov
emerg
repeatedli
unpredict
time
therefor
anticov
drug
specif
target
replic
apparatu
exist
cov
may
effect
anoth
novel
cov
especi
applic
viral
enzym
inhibitor
mab
antivir
peptid
target
well
agent
target
host
cell
receptor
second
limit
number
anim
model
avail
infect
caus
even
sar
mer
experi
use
suitabl
anim
model
mice
transgen
encod
nonhuman
primat
avail
design
research
biosafeti
level
laboratori
experi
technic
demand
last
import
mild
clinic
sever
infect
caus
togeth
absenc
new
sar
case
made
recruit
patient
clinic
trial
difficult
reduc
incent
pharmaceut
compani
develop
specif
antivir
drug
cov
infect
continu
threat
merscov
global
health
secur
year
first
discoveri
present
golden
opportun
tackl
current
obstacl
develop
new
anticov
drug
prudent
wellorgan
multidisciplinari
intern
collabor
network
consist
clinician
virologist
drug
develop
coupl
polit
commit
form
carri
clinic
trial
use
anticov
drug
alreadi
shown
safe
effect
vitro
andor
anim
model
priorit
virusbas
hostbas
treatment
option
clinic
develop
despit
report
larg
number
virusbas
hostbas
treatment
option
potent
vitro
activ
sar
mer
like
fulfil
potenti
clinic
set
forese
futur
drug
one
major
limit
prevent
proceed
beyond
vitro
stage
first
mani
drug
high
ratio
clinic
relev
dosag
exampl
drug
includ
cyclosporin
chlorpromazin
interferon
alfa
second
sever
side
effect
caus
immunosuppress
exampl
use
highdos
ribavirin
may
associ
haemolyt
anaemia
neutropenia
teratogen
cardiorespiratori
distress
merscovinfect
common
marmoset
treat
mycophenol
mofetil
develop
fatal
infect
even
higher
viral
load
lung
extrapulmonari
tissu
untreat
control
agent
target
host
signal
pathway
receptor
may
induc
immunopatholog
furthermor
lack
reliabl
drug
deliveri
method
vivo
particularli
problemat
sirna
agent
previous
use
human
look
ahead
feasibl
option
evalu
clinic
trial
ongo
mer
epidem
includ
monotherapi
combin
therapi
includ
interferon
andor
mab
antivir
peptid
target
merscov
agent
protect
effect
mer
nonhuman
primat
mous
model
moreov
either
market
drug
case
interferon
success
develop
infect
palivizumab
use
respiratori
syncyti
viru
infect
enfuvirtid
use
hiv
infect
long
term
develop
novel
broadspectrum
pancov
antivir
drug
activ
wide
rang
cov
may
becom
ultim
treatment
strategi
circul
emerg
cov
infect
